 There was some positive news for the sector last week, after gene editing player Bluebird Bio received the unanimous backing of the U.S. Food and Drug Administrations Cellular, Tissue, and Gene Therapies advisory committees for two separate therapies targeted at cerebral adrenoleukodystrophy and. 